This site is intended for
US Health Care Professionals only.

This site is intended for US Health Care Professionals only.

Investigational Immune-Biomarkers

Bristol-Myers Squibb is leading the exploration of immune-biomarkers in Immuno-Oncology

Beyond PD-L1, new immune-biomarkers are now being investigated across tumor types. This exploration is focused both within the tumor microenvironment and in the periphery.1-12

Exploratory
immune-biomarkers
within the tumor

TILs/immunoscore (eg, CD4 and CD8 T cells)

Gene expression signatures (immune signatures/inflamed phenotype)

Tumor immune marker expression

Mutational load/burden,
neo-antigens

Exploratory
immune-biomarkers
within the periphery

Immune-monitoring: absolute lymphocyte count, circulating T-cell subsets/MDSCs

TCR sequencing

Gene expression profiling:
peripheral blood

Serum chemokines/cytokines:
interferons, interferon inducible factors, serum soluble factors

Serum proteins

Circulating miRNAs

Antitumor antibodies

SNPs (germline)

Bristol-Myers Squibb is researching the power of immune-biomarkers to help identify patients who are more likely to benefit from Immuno-Oncology therapies.

References

1. Anitei MG, Zeitoun G, Mlecnik B, et al. Prognostic and Predictive Values of the Immunoscore in Patients with Rectal Cancer. Clin Cancer Res. 2014;20(7):1891-1899. 2. Ascierto ML, Kmieciak M, Idowu MO, et al. A signature of immune function genes associated with recurrence-free survival in breast cancer patients. Breast Cancer Res Treat. 2012;131(3):871-880. 3. Brown SD, Warren RL, Gibb EA, et al. Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival. Genome Res. 2014;24(5):743-750. 4. Han Y, Li H, Guan Y, Huang J. Immune repertoire: A potential biomarker and therapeutic for hepatocellular carcinoma. Cancer Lett. 2015;pii:S0304-3835(15)00441-3. 5. Kerr KM, Tsao MS, Nicholson AG, Yatabe Y, Wistuba II, Hirsch Fr. Programmed Death-Ligand 1 Immunohistochemistry in Lung Cancer In what state is this art?. J Thorac Oncol. 2015;10(7):985-989. 6. Komatsu N, Matsueda S, Tashiro K, et al. Gene Expression Profiles in Peripheral Blood as a Biomarker in Cancer Patients Receiving Peptide Vaccination Cancer. 2012;118(12):3208-3221. 7. Luborsky J, Barua A, Shatavi SV, Kebede T, Abramowicz J, Rotmensch J. Anti-Tumor Antibodies in Ovarian Cancer. Am J Reprod Immunol. 2005;54(2):55-62. 8. Schneider BP, Shen F, Miller KD. Pharmacogenetic biomarkers for the prediction of response to antiangiogenic treatment. Lancet Oncol. 2012;13(10):e427-e436. 9. Stanciu AE, Serdarevic N, Hurduc AE, Stanciu MM. IL-4, IL-10 and high sensitivity-CRP as potential serum biomarkers of persistent/recurrent disease in papillary thyroid carcinoma with/without Hashimoto's thyroiditis. Scand J Clin Lab Invest. 2014;75(7):539-548. 10. Wang Z, Han J, Cui Y, Fan K, Zhou X. Circulating microRNA-21 as noninvasive predictive biomarker for response in cancer immunotherapy. Med Hypotheses. 2013;81(1):41-43. 11. Whiteside TL. Immune responses to cancer: are they potential biomarkers of prognosis?. Front Oncol. 2013;3:107. doi:10.3389/fonc.2013.00107. 12. Xu B, Yuan L, Gao Q, et al. Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer. Oncotarget. 2014;6(24):20592-20603.